Nisa Investment Advisors LLC Has $216,000 Stake in Protagonist Therapeutics, Inc. $PTGX

Nisa Investment Advisors LLC increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 37.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,903 shares of the company’s stock after acquiring an additional 1,071 shares during the period. Nisa Investment Advisors LLC’s holdings in Protagonist Therapeutics were worth $216,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC acquired a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at about $27,000. CWM LLC increased its holdings in shares of Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after acquiring an additional 407 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company’s stock valued at $58,000 after acquiring an additional 728 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Protagonist Therapeutics by 141.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company’s stock valued at $59,000 after acquiring an additional 710 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new position in shares of Protagonist Therapeutics during the 1st quarter valued at about $68,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Down 3.4%

Shares of PTGX stock opened at $75.95 on Tuesday. The stock has a 50 day moving average of $66.98 and a two-hundred day moving average of $56.73. Protagonist Therapeutics, Inc. has a 12 month low of $33.31 and a 12 month high of $93.25. The company has a market capitalization of $4.72 billion, a P/E ratio of 108.50 and a beta of 2.21.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%.The firm had revenue of $5.55 million during the quarter, compared to the consensus estimate of $8.32 million. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the completion of the sale, the director owned 5,130 shares in the company, valued at approximately $418,710.60. This trade represents a 70.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 20,000 shares of company stock valued at $1,473,440. 4.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

PTGX has been the topic of a number of research analyst reports. JMP Securities raised their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a report on Thursday, August 7th. Wedbush raised their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a report on Tuesday, October 28th. Truist Financial raised their target price on Protagonist Therapeutics from $76.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup raised their target price on Protagonist Therapeutics from $72.00 to $96.00 and gave the company a “buy” rating in a report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.08.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.